From “Undruggable” to Attainable: Genesis Therapeutics’ AI Journey Bolstered by US$200 Million Series B Funding

Genesis Therapeutics' AI Journey Bolstered by US$200 Million Series B Funding

Series B funding propels Genesis Therapeutics into the next phase of AI-driven medical breakthroughs.

Genesis Therapeutics, an artificial intelligence (AI)-focused company in the pharmaceutical sector based in Burlingame, California, has raised US$200 million in a successful Series B funding round. The company, which is known for leveraging AI technologies to develop innovative medicines for individuals grappling with critical diseases, aims to use this funding to advance to clinical stages. This will also assist them in further enhancing their AI platform and diversifying their discovery pipeline.

The latest funding round saw participation from a diverse set of investors. While a U.S.-based life-sciences-focused investor led the round, returning investors like Andreessen Horowitz (a16z) Bio + Health—who led the initial seed financing—also took part. Other notable investors included Fidelity Management & Research Company, NVIDIA’s NVentures, BlackRock, T. Rowe Price Associates, Inc., Rock Springs Capital, Radical Ventures and Menlo Ventures.

Driving AI drug development and expanding patient reach

With this financing, Genesis plans to fast-track their current AI-driven projects into clinical phases. They will also be dedicating resources to their Genesis Exploration of Molecular Space (GEMS) platform, which is known for its advanced AI methods that provide predictive insights and aid in drug discovery. One of their primary objectives is to utilize this platform to target and make advancements against medical conditions that were previously deemed “undruggable”.

The GEMS platform stands out due to its proprietary AI methods, which are geared towards producing unique molecules. This technology can predict various drug properties, including efficacy, selectivity, pharmacokinetics and potential toxicity, and is specially designed to identify drug candidates for challenging targets.

Evan Feinberg, Ph.D., the CEO of Genesis, highlighted the potential of AI in transforming the drug discovery landscape. He expressed optimism about the company’s growth, especially with the addition of new investors who come from both biotech and AI backgrounds.

Vijay Pande, Ph.D., a key figure at a16z Bio + Health, underscored Genesis’ proficiency in integrating deep learning with simulations from the get-go. He praised the company’s GEMS platform and its capabilities in tackling previously undruggable conditions, emphasizing the blend of technology and biomedicine as a significant catalyst for future medical innovations.

With this Series B funding, Genesis Therapeutics’ total capital now surpasses US$280 million. Alongside this, US$24 million of SAFE notes from an earlier round led by Radical Ventures were converted as the Series B concluded. Before this, they raised a US$52 million Series A led by Rock Springs Capital and a US$4 million seed round led by a16z Bio + Health. Moreover, the company has formed partnerships with industry giants like Genentech and Eli Lilly in the past.

Also read:

Header image courtesy of Pexels

Press release link:


Share on facebook
Share on twitter
Share on linkedin
Share on email


Eightfold AI Joins Department of Commerce Initiative for AI Safety

Eightfold AI, an AI-driven talent solution company, has announced its involvement in a Department of Commerce initiative aimed at fostering the development and deployment of trustworthy and secure artificial intelligence (AI). This initiative, under the auspices of the National Institute of Standards and Technology (NIST), introduces the U.S. AI Safety Institute Consortium (AISIC). The consortium aims to unite a diverse group of stakeholders, encompassing AI developers, users, academia, government and industry experts and civil society bodies to advance the mission of safe and reliable AI.

What Are Shadow Boards in the Workplace? Pros and Cons

In today’s rapidly evolving business landscape, companies are constantly seeking innovative ways to maintain a competitive edge. An intriguing development in this arena is the emergence of “shadow boards”—dynamic groups within organizations designed to complement the official board of directors by offering fresh perspectives on critical business strategies. This article explores the role of shadow boards in the modern workplace and highlights their benefits, challenges and how they are shaping future business practices.

Anthropologie and Pinterest Unveiled 2024 Bridal Trends at NYC Pop-Up Event

Anthropologie Weddings, a bridal collection from the global lifestyle brand Anthropologie, in collaboration with AnthroLiving and Terrain, debuted the Anthropologie Weddings x Pinterest Trend Pop-Up. This event, developed in partnership with Pinterest, was designed to bring emerging bridal trends, as identified by Pinterest Predicts, into tangible experiences. Offering inspiration and early access to trends, the pop-up showcased bridal designs, décor and lifestyle options that could be personalized for unique wedding visions.

Hello Group Introduces inSpaze: An Immersive Social App for Apple Vision Pro

Hello Group Inc., a prominent mobile social entertainment provider in China, introduces its immersive social application, inSpaze, an immersive social application exclusively for Apple Vision Pro users in the United States. This application, crafted for visionOS, leverages advanced technologies like 3Ds, Reality Converter and Reality Composer Pro, offering a unique spatial computing experience that connects users worldwide through Spatial Audio and 3D interactive content.

Are There More Layoffs Coming in 2024?

Even as we kick off the new year, the horrors of the year past are not behind us. In 2023, major tech companies undertook big layoffs—in January last year, Google reduced its headcount by 6% (it also recently hinted at a fresh round of layoffs this year); in December 2023, Spotify laid off 17% of its staff and more companies gave out pink slips. This trend has been ongoing for a couple of years since the pandemic shook global markets.